Alle Vortragsslides


[GS2-01] Age-related breast cancer risk estimates for the general population based on sequencing of cancer predisposition genes in 19,228 breast cancer patients and 20,211 matched unaffected controls from US based cohorts in the CARRIERS study



Couch FJ, Hu C, Hart SN, Gnanaolivu RD, et al.




The authors conclude that: Results from the CARRIERS cohort-based study establish that mutations in known breast cancer predisposition genes are associated with only moderate risks of breast cancer in the general population. However, risks are substantially increased for BRCA1 and BRCA2 but not ATM, CHEK2 or PALB2 mutations in those £50 years of age. The age-related estimates of breast cancer risk for each of the hereditary cancer panel genes in this study may inform selection of individuals in the general population who may benefit from genetic testing and associated risk management strategies. 




[GS2-02] Efficacy and utilization trends of adjuvant chemotherapy for stage I, II, and III breast cancer in the elderly population: A National Cancer Database (NCDB) analysis



Sinha S, Panebianco L, Wu X, Wang D, et al.




The authors conclude that: Adjuvant chemotherapy is considered standard of care for patients with early-stage breast cancer. Elderly patients are more likely to get adjuvant chemotherapy based on histology, age<80, grade, stage, and hormone receptor status. In this study, we also learn that the OS benefit with adjuvant chemotherapy is significant in all subgroups analyzed for the elderly population.




[GS2-03] Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients



Spring LM, Fell G, Arfe A, Trippa L, et al.




The authors conclude that: Achieving pCR following neoadjuvant chemotherapy is associated with significantly improved disease recurrence and survival, particularly for triple negative and HER2+ breast cancer. The similar outcomes with/without adjuvant chemotherapy in patients who attain pCR after neoadjuvant chemotherapy likely reflects tumor biology and suggests adjuvant chemotherapy could potentially be abbreviated in certain circumstances, and highlights the need for further research to evaluate clinical utility of escalation/de-escalation strategies in the adjuvant setting based on neoadjuvant response for patients with localized breast cancer.




[GS2-04] Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer



Martín M, Barrios CH, Torrecillas L, Ruiz-Borrego M, et al.




The authors conclude that: In our study, the addition of adjuvant X after standard (neo) adjuvant anthracycline and/or taxane-containing chemotherapy was not associated with a statistically significant improvement of DFS or OS compared to observation in pts with early TNBC. However, in a subgroup analysis a significant DFS and OS improvement was observed with X in pts with non-basal phenotype.




[GS2-05] Impact of the delayed initiation of adjuvant chemotherapy in the outcomes of triple negative breast cancer



Morante Z, Ruiz R, De la Cruz - Ku G, Namuche F, et al.




The authors conclude that: Delayed initiation of adjuvant chemotherapy in TNBC patients over 30 days is associated with a decrease in RFS and OS rates. The greater the delay, the worse the outcomes. As this represents a feasible opportunity for improvement, every attempt should be made to avoid delayed adjuvant chemotherapy initiation in this high-risk group of patients.




[GS2-06] GS2-06 Discussant Joe Sparano 1578, 864, 1698








[GS2-07] PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer



Pivot X, Romieu G, Debled M, Pierga J-Y, et al.




The authors conclude that: The choice of the non-inferiority margin will remain inherently a subject of controversy especially in the context of oncology trials where the primary outcome is survival and the least additional death could be considered unacceptable questioning the very feasibility of such trials. Nevertheless, PHARE failed to show that 6 months of adjuvant trastuzumab was non-inferior to 12 months. The standard of care should remain 12 months of adjuvant trastuzumab.



San Antonio - Mosaic on a pillar of streetcar station